ClinicalTrials.gg
Not yet recruitingNCT05161026REMODALLOUpdated Dec 16, 2021

Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry

An interventional study of Bone osteodensitometry in Myeloid Leukemia, Acute, sponsored by University Hospital, Caen. Not yet recruiting at 4 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-16.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Leukemia, Myeloid, Acute with a site in France — 64 open to participants now, 96 under way, 21 of them phase 3. Leukemia, Myeloid, Acute · France.

Planned enrollment
126th of 289
120 · median 100
Started
2021
with 25 others
No phase
29 of 342
9 open now
Primary completion
2026-12
later than 29 of 95 live
Registered
260th of 342
by date

Among the 342 studies in Leukemia, Myeloid, Acute with a site in France, this one is the 126th largest by planned enrollment of the 289 interventional ones that give a count, is one of 26 that started in 2021, is one of 29 with no phase, reaches primary completion later than 29 of the 95 other live ones, and was the 260th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

64 of the 342 studies in Leukemia, Myeloid, Acute with a site in France are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Leukemia, Myeloid, Acute with a site in France, or all of them as a file.
02

Study summary

Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.

Read the detailed description

Allo-HSCTs performed for the treatment of hematologic malignancies has been increasing in recent years. There is therefore a growing interest in the quality of life of these patients and in particular for the bone complications of the transplant. Indeed, it was found a high incidence of osteoporosis / osteopenia in this population associated with an increased risk of osteoporotic fracture from 6 to 9 times compared to the general population.

This study will evaluate the variation of mineral density and bone microarchitecture parameters by bone densitometry with measurement of trabecular bone score and fracturing risk before and after allogeneic HSCTs transplant, at predefined times. It's also evaluating pain scale, fracture incidence and bone remodeling markers.

03

Conditions studied

  • Myeloid Leukemia, Acute

Keywords

  • allo-HSCTs transplant
  • osteoporosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cytological diagnosis of acute myeloid leukemia (AML) with indication for a allo-HSCTs transplant
  • Patient affiliated to the social security system
  • For women of childbearing age, use of reliable throughout the study in accordance with the CPR of the drugs used.
  • The patient must be able to comply with study visits and per protocol procedures
  • Patient who has been informed of the study and has signed his

Exclusion criteria

Exclusion Criteria:

  • Person under guardianship or curatorship, or unable to understand the purpose of the study.
  • Hematologic other than AML
  • History of neoplasia with bone involvement (sarcoma, multiple myeloma, ...) and/or any solid cancer less than 5 years old
  • History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies
  • Known bone involvement related to AML at diagnosis
  • Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies
  • Corticotherapy > 3 months at a dose > 7.5mg/day prior to the diagnosis of hematological disease
  • Autograft or anterior allograft
  • Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure ( \< or = at 30ml / min / 1.73m2)
  • Pregnant or lactating woman
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Patients with AML

    Patients with AML

    Other: Bone osteodensitometry

Interventions

  • OtherBone osteodensitometry

    Evaluation of bone osteodensitometry

06

What researchers measure

Primary outcomes

  1. bone mineral density evaluation

    bone mineral density evaluation post-transplant

    Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant

Secondary outcomes

  1. bone mineral density evaluation

    long term bone mineral density evaluation

    Time frame: change over time between 24 months and 36 months post-transplant

  2. Bone architectural abnormalities and fracture risk

    evaluation of bone architectural abnormalities and fracture risk

    Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant

  3. bone remodeling markers

    Dosage of bone remodeling markers

    Time frame: change over time between diagnostic, transplant, 6 months and 12 months post-transplant

  4. Pain evaluation

    Pain evaluation (EVA)

    Time frame: change over time between diagnostic, transplant, 6 months, 12 months, 24 months and 36 months post-transplant

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Dec 2026, 59 months later.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 59 months is above that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Dec 16, 2021
StartEst.
Dec 10, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Dec 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161026
Responsible party
Sponsor
First posted
Dec 16, 2021
Start date
Dec 10, 2021 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 16, 2021

Study contacts

Agathe FARGE, PhD
Contact
farge-a@chu-caen.fr
+33 2.31.27.21.40
DRCI secretary
Contact
drci-sec@chu-caen.fr
+33.2.31.06.57.81

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion